Cargando…

Efficacy of inverso isomer of CendR peptide on tumor tissue penetration

The dense extracellular matrix and high interstitial fluid pressure of tumor tissues prevent the ability of anti-tumor agents to penetrate deep into the tumor parenchyma for treatment effects. C-end rule (CendR) peptides can enhance the permeability of tumor blood vessels and tumor tissues via bindi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ruifeng, Shen, Qing, Li, Xue, Xie, Cao, Lu, Weiyue, Wang, Songli, Wang, Jing, Wang, Dongli, Liu, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6146380/
https://www.ncbi.nlm.nih.gov/pubmed/30245969
http://dx.doi.org/10.1016/j.apsb.2018.06.006
_version_ 1783356385072775168
author Wang, Ruifeng
Shen, Qing
Li, Xue
Xie, Cao
Lu, Weiyue
Wang, Songli
Wang, Jing
Wang, Dongli
Liu, Min
author_facet Wang, Ruifeng
Shen, Qing
Li, Xue
Xie, Cao
Lu, Weiyue
Wang, Songli
Wang, Jing
Wang, Dongli
Liu, Min
author_sort Wang, Ruifeng
collection PubMed
description The dense extracellular matrix and high interstitial fluid pressure of tumor tissues prevent the ability of anti-tumor agents to penetrate deep into the tumor parenchyma for treatment effects. C-end rule (CendR) peptides can enhance the permeability of tumor blood vessels and tumor tissues via binding to neuropilin-1 (NRP-1), thus aiding in drug delivery. In this study, we selected one of the CendR peptides (sequence RGERPPR) as the parent l-peptide and substituted d-amino acids for the l-amino acids to synthesize its inverso peptide (D)(RGERPPR). We investigated the NRP-1 binding activity and tumor-penetrating ability of (D)(RGERPPR). We found that the binding affinity of (D)(RGERPPR) with NRP-1 and the cellular uptake was significantly higher than that of RGERPPR. Evans Blue tests revealed that (D)(RGERPPR) exhibited improved tumor-penetrating ability in C6, U87 and A549 tumor-bearing nude mice. Using nude mice bearing A549 xenograft tumors as a model, we found that the rate of tumor growth in the group co-administered with (D)(RGERPPR) and gemcitabine (Gem) was significantly lower than the gemcitabine-treated group with a tumor suppression rate (TSR%) of 55.4%. Together, our results demonstrate that (D)(RGERPPR) is a potential tumor-penetrating peptide.
format Online
Article
Text
id pubmed-6146380
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-61463802018-09-21 Efficacy of inverso isomer of CendR peptide on tumor tissue penetration Wang, Ruifeng Shen, Qing Li, Xue Xie, Cao Lu, Weiyue Wang, Songli Wang, Jing Wang, Dongli Liu, Min Acta Pharm Sin B Original article The dense extracellular matrix and high interstitial fluid pressure of tumor tissues prevent the ability of anti-tumor agents to penetrate deep into the tumor parenchyma for treatment effects. C-end rule (CendR) peptides can enhance the permeability of tumor blood vessels and tumor tissues via binding to neuropilin-1 (NRP-1), thus aiding in drug delivery. In this study, we selected one of the CendR peptides (sequence RGERPPR) as the parent l-peptide and substituted d-amino acids for the l-amino acids to synthesize its inverso peptide (D)(RGERPPR). We investigated the NRP-1 binding activity and tumor-penetrating ability of (D)(RGERPPR). We found that the binding affinity of (D)(RGERPPR) with NRP-1 and the cellular uptake was significantly higher than that of RGERPPR. Evans Blue tests revealed that (D)(RGERPPR) exhibited improved tumor-penetrating ability in C6, U87 and A549 tumor-bearing nude mice. Using nude mice bearing A549 xenograft tumors as a model, we found that the rate of tumor growth in the group co-administered with (D)(RGERPPR) and gemcitabine (Gem) was significantly lower than the gemcitabine-treated group with a tumor suppression rate (TSR%) of 55.4%. Together, our results demonstrate that (D)(RGERPPR) is a potential tumor-penetrating peptide. Elsevier 2018-09 2018-06-30 /pmc/articles/PMC6146380/ /pubmed/30245969 http://dx.doi.org/10.1016/j.apsb.2018.06.006 Text en © 2018 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original article
Wang, Ruifeng
Shen, Qing
Li, Xue
Xie, Cao
Lu, Weiyue
Wang, Songli
Wang, Jing
Wang, Dongli
Liu, Min
Efficacy of inverso isomer of CendR peptide on tumor tissue penetration
title Efficacy of inverso isomer of CendR peptide on tumor tissue penetration
title_full Efficacy of inverso isomer of CendR peptide on tumor tissue penetration
title_fullStr Efficacy of inverso isomer of CendR peptide on tumor tissue penetration
title_full_unstemmed Efficacy of inverso isomer of CendR peptide on tumor tissue penetration
title_short Efficacy of inverso isomer of CendR peptide on tumor tissue penetration
title_sort efficacy of inverso isomer of cendr peptide on tumor tissue penetration
topic Original article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6146380/
https://www.ncbi.nlm.nih.gov/pubmed/30245969
http://dx.doi.org/10.1016/j.apsb.2018.06.006
work_keys_str_mv AT wangruifeng efficacyofinversoisomerofcendrpeptideontumortissuepenetration
AT shenqing efficacyofinversoisomerofcendrpeptideontumortissuepenetration
AT lixue efficacyofinversoisomerofcendrpeptideontumortissuepenetration
AT xiecao efficacyofinversoisomerofcendrpeptideontumortissuepenetration
AT luweiyue efficacyofinversoisomerofcendrpeptideontumortissuepenetration
AT wangsongli efficacyofinversoisomerofcendrpeptideontumortissuepenetration
AT wangjing efficacyofinversoisomerofcendrpeptideontumortissuepenetration
AT wangdongli efficacyofinversoisomerofcendrpeptideontumortissuepenetration
AT liumin efficacyofinversoisomerofcendrpeptideontumortissuepenetration